Small molecule multitarget antiangiogenic inhibitor treatments for advanced thymic epithelial tumors: A retrospective study
Abstract Background Thymic epithelial tumors (TETs) are rare malignant tumors with limited treatment options. No established second‐line treatment regimen is available following the preferred first‐line chemotherapy, resulting in unsatisfactory efficacy and poor prognosis for patients with advanced...
Main Authors: | Wanji Shen, Ying Jin, Ying Yu, Ning Chen, Yun Fan |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2024-01-01
|
Series: | Thoracic Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1111/1759-7714.15167 |
Similar Items
-
Current Treatment Approaches for Thymic Epithelial Tumors
by: Alfredo Tartarone, et al.
Published: (2023-05-01) -
An Overview of the Use of Anti-Angiogenic Agents in the Treatment of Thymic Epithelial Tumors
by: Apostolos C. Agrafiotis, et al.
Published: (2023-12-01) -
Chinese expert consensus on the diagnosis and treatment of thymic epithelial tumors
by: Chunwei Xu, et al.
Published: (2023-04-01) -
Thymic Epithelial Tumors: An Evolving Field
by: Elisabetta Kuhn, et al.
Published: (2023-01-01) -
Immunobiology of Thymic Epithelial Tumors: Implications for Immunotherapy with Immune Checkpoint Inhibitors
by: Valentina Tateo, et al.
Published: (2020-11-01)